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Abstract: Stimuli-responsive materials are very attractive candidates for on-demand drug delivery
applications. Precise control over therapeutic agents in a local area is particularly enticing to regulate
the biological repair process and promote tissue regeneration. Macromolecular therapeutics are
difficult to embed for delivery, and achieving controlled release over long-term periods, which is
required for tissue repair and regeneration, is challenging. Biohybrid composites incorporating
natural biopolymers and electroconductive/active moieties are emerging as functional materials to be
used as coatings, implants or scaffolds in regenerative medicine. Here, we report the development
of electroresponsive biohybrid composites based on Bombyx mori silkworm fibroin and reduced
graphene oxide that are electrostatically loaded with a high-molecular-weight therapeutic (i.e., 26 kDa
nerve growth factor-β (NGF-β)). NGF-β-loaded composite films were shown to control the release
of the drug over a 10-day period in a pulsatile fashion upon the on/off application of an electrical
stimulus. The results shown here pave the way for personalized and biologically responsive scaffolds,
coatings and implantable devices to be used in neural tissue engineering applications, and could be
translated to other electrically sensitive tissues as well.
Keywords: growth factor; stimuli-responsive delivery; nerve repair; conductivity; biohybrid; silk;
reduced graphene oxide
1. Introduction
Drug delivery technologies are a multibillion-dollar global industry [1]. Driving the increase in
research and development efforts [2] is the market need for devices and ‘smart’ implants or scaffolds
capable of delivering active agents at specific rates. These systems can be controlled by either physical
(e.g., electromagnetic fields, electrical stimulation, temperature) or (bio)chemical (e.g., enzymes, ions,
pH) stimuli, in single or combined mechanisms. These technologies enable greater control over the
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delivery of drugs compared to traditional systems that rely on passive delivery, which cannot be
modified in response to therapeutic demand [3].
Electrical stimulation in particular can offer control over drug delivery according to the strength,
duration and frequency of the applied field. Consequently, electroconductive/active biomaterials have
received great attention in recent years for wound healing and tissue engineering applications due
to their potential to allow direct delivery of electrical signals, which are stimulatory to cells/tissues
and further trigger a controlled/responsive release of therapeutics to the site of interest [4], potentially
wirelessly [5]. Responsiveness to an electric field is an inherent feature of electroconductive/active
materials, and their properties can be tailored to suit the delivery of various pharmacological agents
and biomolecules. Conductive components used for biomaterial design range from conjugated
polymers (e.g., polypyrrole (PPy), polyaniline (PANI), poly (3,4-ethylenedioxythiophene) (PEDOT) and
their copolymers), to metallic nanoparticles and carbon-based materials (e.g., carbon nanotubes and
graphene family materials) [6–11]. A mechanism of electrical conduction involves electron mobility
along the backbone of the conjugated polymers and ionic groups appended to or complexed with the
conjugated polymers and electrolytes in the medium [12]. High versatility and functionality can be
achieved with carbon-based materials. Graphene derivatives in particular have shown advantageous
properties for several electrically sensitive tissues, such as nerves [13], but their use as standalone
materials is challenging. Biohybrid composites allow flexibility in manufacturing. Combining a protein
found in nature as the matrix phase with a conductive component to provide additional functionality
offers a multifunctional platform for developing coatings, implants or scaffolds for tissue engineering
to match a variety of tissues in surgical reconstruction and regeneration [14].
The response achieved by releasing domain-sized macromolecular therapeutics (e.g., high-molecular-
weight drugs >20 kDa, such as proteins, genes, growth factors or siRNA) is challenging due to their
larger molecular dimensions and difficulties in their absorption or adsorption to the carrier system,
which is limited by diffusion and surface area [15–17]. Most electroresponsive systems described
for on-demand drug delivery make use of low-molecular-weight (LMW) drugs, which can be easily
embedded in a scaffold. LMW drugs are good candidates for disease treatment as they easily transverse
through organs and tissues, but they also impart non-specificity, increase the incidence of side effects
and are rapidly eliminated from the body, therefore requiring frequent dosing [17]. Furthermore,
most responsive systems suffer from short release duration (in the range of minutes to days) of the
therapeutic [18–20], while tissue regeneration and repair often requires long-term drug release [21].
In particular, the lifelong disability related to peripheral nerve injury (PNI) continues to be a
common condition occurring in about 3–10% of trauma patients, with an estimated one million surgical
reconstruction procedures performed annually between Europe and the US [9,22,23]. Peripheral nerve
axons can spontaneously regenerate to a certain extent after injury, but the probability of recovery
decreases as the level of injury increases. Current therapeutic procedures are surgical, employing
biomaterials to bridge nerve defects with varying degrees of success [24–26]. To enhance the probability
of successful outcomes, the use of pharmacological agents and biomolecules, such as microRNAs or
growth factors to promote nerve regeneration have gained attention over the last few years [27–29].
Neurotrophins are one of many examples of these, which regulate extracellular signaling, neuronal
survival and differentiation and axonal regeneration [30]. Among the wide range of neurotrophins,
nerve growth factor (NGF) plays a critical role in the development and phenotype maintenance of the
peripheral nervous system [31], assisting the functional recovery of injured nerves (by contributing to
maintaining the synaptic activity of neurons, preventing apoptosis or regulating the functions of other
cell types [32]). However, the effective administration of a domain-sized macromolecular therapeutic
such as NGF remains an issue.
With a view to treat nerve injuries and develop a combinatorial tissue engineered approach,
we report here the development of electroresponsive biohybrid composites based on Bombyx mori silk
fibroin (SF), which acts as the continuous phase, and reduced graphene oxide (rGO) as a conductive
dispersed phase. These biohybrid composites enable the controlled release of nerve growth factor-β
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(NGF-β, 26 kDa) over long-term periods upon the application of a pulsatile electrochemical stimulus
(Scheme 1).
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Scheme 1. Schematic representation of electroresponsive biohybrid composites based on silk fibroin
and reduced graphene oxide for the controlled release of macromolecular therapeutics.
2. Materials and Methods
2.1. Preparation of Regenerated Silk Fibroin
Extraction and purification of silk fibroin (SF) from Bombyx mori silkworm cocoons was carried
out as previously described [33]. In brief, cocoons (Wildfibres; Birmingham, UK) were dewormed,
sliced into small pieces, and degummed in 0.02 M sodium carbonate (Sigma-Aldrich; Gillingham,
UK) for 30 in. Degummed SF fibres were thoroughly washed in deionized (DI) water and air-dried
overnight. The fibres were then dissolved in 7.9 M lithium bromide (Sigma-Aldrich, UK) solution
at 60 ◦C for 4 h, then dialyzed against 5 L of DI water over the course of 3 days, with regular water
changes. The regenerated SF solution was centrifuged, cast onto polystyrene dishes (Sigma-Aldrich,
UK) and dried at 60 ◦C for 2 h in a forced air-circulation oven (Memmert Universal; Schwabach,
Germany). The resulting films were subsequently peeled off and kept in sealed vials as stock material
for further use.
2.2. Preparation of Electroconductive Biohybrid Composite Films
Graphene oxide (GO) flakes (2-DTech; Manchester, UK) (<4 µm lateral width and <2 layers,
as quoted by the manufacturer) were dispersed in ≥95% v v−1 formic acid (Sigma-Aldrich, UK),
sonicated at 80 Hz for 2 h (Elmasonic P60H) (Elma Schmidbauer; Singen, Germany) and hom geniz
with SF by mixing for 1 h at room temperature. Reductio of GO was perfor ed in situ [34,35]
following a p eviously described protocol [36,37], i which 1 µL of ≥98% v v−1 hydrazine monohydrate
(Sigma-Aldrich, UK) was added for every 3 mg of GO and heated at 95 ◦C in an oil bat under constant
stirring for a minimum period of 3 h. Film membranes w re then prepared by solution casting a d
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evaporation. The prepared silk-based solutions were cast onto polystyrene dishes (Sigma-Aldrich, UK)
and the solvent was evaporated overnight in a fume hood, giving films at controlled rGO loadings
(control 0, 10, 20, 30 and 40% wt. rGO/SF). The as-prepared films were annealed by immersion in a
bath of 80% v v−1 ethanol for 20 min to induce β-sheet conformational transition, washed with DI
water and dried for 24 h while sandwiched between filter paper (Whatman) (Sigma-Aldrich, UK) to
prevent curling or folding. The resulting films were stored in a desiccator until further use.
2.3. Characterization of the Electroconductive Biohybrid Composites
The visual appearance of the top surface of the films were observed at room temperature using an
optical DS microscope (Olympus) fitted with a digital camera, and the surface was further examined
with a JEOL JSM6700F field emission scanning electron microscope (FESEM) (JEOL; Tokyo, Japan).
For the latter, samples (n = 2 per type) were mounted on aluminum stubs with double-sided adhesive
carbon tape and gold-coated prior to visualization at 5 kV, with a working distance of ~8 mm and
×1k magnification.
The chemical structures of the films (n = 2 per type) were analyzed with a Fourier transform
infrared (FTIR) spectrometer (PerkinElmer 2000) equipped with a zinc selenide (ZnSe) crystal in
attenuated total reflectance (ATR) mode. For each measurement, 32 scans were recorded with a
resolution of 4 cm−1 and wavenumbers from 4000 to 600 cm−1.
The swelling characteristics of the films (n = 3 per type) were investigated by weight differences
between the hydrated and dry states. Samples (15 mm × 15 mm) were immersed in 10 mL of DI
water and incubated at 37 ◦C in a water bath overnight. Excess water was removed by sandwiching
the samples in filter paper and weighing immediately afterwards with a high-precision analytical
balance. Three measurements were taken per sample. The swelling ratio was calculated according to
Equation (1):




Electrical conductivity measurements were performed with a four-point probe automated electrical
conductivity and resistivity system (A4P-200 MicroXACT, US) [38], using MicroXACT LabView-based
automated software. Conductivity of the samples (n = 4 per type) was assessed in different locations
across the surface in both the dry and hydrated states. To test the hydrated samples, films were
immersed in 10 mL of phosphate buffered saline (PBS) overnight, with excess removed by blotting
with tissue paper prior to testing.
2.4. In Vitro NGF-β Loading and Release Study
2.4.1. Electrochemical Loading
Recombinant rat nerve growth factor β (NGF-β) (Thermo Fisher Scientific; Altrincham, UK) was
diluted into PBS to make a 1 nM solution. The material samples were then actively/electrochemically
loaded with NGF-β (using 4 mL of a 1 nM NGF-β solution in PBS as the electrolyte bath).
A three-electrode cell was composed of an Ag/AgCl reference electrode, an Au counter electrode and a
glassy carbon electrode with the sample material on its surface [1]. Growth factor loading was achieved
by applying a constant potential of 0.6 V for 30 min, after which the samples were rinsed in PBS to
wash away any residual unincorporated agent.
2.4.2. NGF-β Release
Chronoamperometric studies were completed using a PalmSens EmStat 3+ potentiostat connected
to a computer and PSTrace software (v. 7.4) supplied by Alvatek; Tetbury, UK). The cell comprised
a three-electrode system with an Ag/AgCl reference electrode, an Au counter electrode and a glassy
carbon working electrode with the sample material on its surface in PBS (0.01 M, 4 mL). Prior to each
experiment, there was ‘quiet time’ for 10 s, the initial potential was 0 V, the high potential was 0.7 V,
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the low potential was −0.5 V, the initial scan was positive, the current was measured at 1 mV intervals,
the scan rate used for all experiments was 50 mV s−1 and the stimulation lasted 62 s. After stimulation
of the material, the cell was allowed to rest for 24 h to allow the released drug to equilibrate in the
PBS solution. After allowing the drug to equilibrate in solution post stimulation, a 10 µL aliquot was
taken from the electrolyte solution and diluted with 100 µL of PBS before being frozen prior to analysis.
Passive release controls were run in parallel with the electrically stimulated samples.
2.4.3. NGF-β Quantification
Quantification of the released NGF-β was achieved by means of ELISA using a commercial kit
(Thermo Fisher Scientific, UK). Absorbance measurements were taken in triplicate using a Molecular
Devices FlexStation 3 plate reader at 450 nm. Data were reported as the cumulative release by the
percentage of the total mass of the growth factor loaded on the films.
2.5. In Silico Studies
In silico toxicity screening was carried out using Derek Nexus (v. 6.0.1) (Lhasa Ltd.; Leeds,
UK), and the selected structural, topological and physicochemical descriptors were calculated
using Bioclipse® (v. 2.6) (Bioclipse project; Uppsala University, Sweden) and Molecular Operating
Environment (MOE®; v. 2014.0901) (Chemical Computing Group Inc.; Montreal, Canada), with
information related to NGF-β sourced from the protein data bank (.pdb) files obtained from the
Research Collaboratory for Structural Bioinformatics (RSCB) Protein Data Bank.
2.6. Data Analysis
Statistical analysis was performed with GraphPad Prism 8 (San Diego, CA, USA) and checked for
normality. Normally distributed data were presented as standard deviation (SD, error bars) of the
mean values. For parametric data and multiple comparisons, significance was assessed by one-way
ANOVA (one independent variable) or two-way ANOVA (two independent variables), with Tukey’s
post hoc analysis test. A value of p < 0.05 was considered statistically significant.
3. Results and Discussion
Graphene oxide (GO) flakes were homogenized with regenerated silk fibroin in formic acid at
high loadings (10–40% wt. GO/SF) and reduced in situ with hydrazine, as detailed in the methodology,
until a stable co-suspension was formed. The co-suspensions were cast and the volatiles allowed to
evaporate, yielding thin film substrates (thickness < 80 µm) that were annealed in ethanol. The as-cast
pristine silk sample was semitransparent to light and became opaque and black after incorporation
of rGO (Figure 1(a1)). FE-SEM micrographs of the surface topography of the films (Figure 1(a2))
exhibited differences with rGO incorporation; pristine silk exhibited smooth topography whereas
increased topographical features were evident with increased rGO content. B. mori silk fibroin-based
materials produced from solutions in formic acid tend to be β-sheet rich [39] after evaporation of
the formic acid, which renders them insoluble in water. Analysis of the films via attenuated total
reflectance infrared spectroscopy (FTIR-ATR) (Figure S1) confirmed the presence of β-sheets in the
ethanol-annealed films, exhibiting peaks in the amide I region between 1621 and 1637 cm−1 and a
peak at 1520 cm−1 in the amide II region characteristic of β-sheets [39]. B. mori silk fibroin-based
materials absorb water, however, we observed no major differences in the swelling ratio of the films
with the inclusion of rGO (Figure 1b), with a swelling ratio of ~25% for all films, regardless of rGO
content. The mechanism of drug loading and release from a scaffold varies upon the molecular weight
of the drug and may be affected by swelling. LMW drugs effectively penetrate the polymer matrix,
and their release is more affected by diffusion (e.g., swelling and matrix) and solute size/hydrodynamic
radius [40]. A molecular weight cutoff does exist, above which the drug is too large to diffuse into
the matrix (e.g., macromolecular therapeutics), so the quantity of the drug loaded is controlled by the
surface area available for adsorption [16]. In the scenario of this work, we did not need to consider
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the influence of swelling on the release of the growth factor since it was electrostatically adsorbed on
the surface.
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Figure 1. Electroconductive/active silk-based scaffolds. (a) Representative (a1) macroscopic visual
appearance of silk-based films and (a2) FESEM micrographs at increasing rGO loading; scale bars at
5 mm and 10 µm respectively. (b) Swelling ratio (n = 3 per sample type). (c) Conductive properties
(n = 4 per sample type) in the dry and hydrated states. The differences between the experimental groups
were analyzed by one-way or two-way ANOVA using Tukey’s post hoc test for multiple comparison.
n.s, nonsignificant; ** p < 0.01, **** p < 0.0001.
The conductivity of the biohybrid composites was examined in the dry state as well as hydrated
state, representing a more physiologically relevant environment (Figure 1c). Pristine silk films showed a
conductivity of 9 × 10−8 S cm−1 in the dry state. The conductivity increased up to 3 × 10−5 S cm−1 as the
content of the filler increased. After hydration, the conductance was dominated by the presence of both
the substrate and the electrolytes from the buffered medium, with the conductivity increasing up to
three orders of magnitude for the lower rGO loadings (10–30% wt.), analogous to other carbon-loaded
materials [41]. The higher conductivity measured in the hydrated state of the samples could be further
explained in terms of proton/ion conduction [42–45] by the Grotthuss mechanism, which describes the
process of proton hopping across water networks from one water molecule to another across H9O4+ or
H5O2+ cations, and could plausibly be enhanced by incorporating pristine graphene [14].
Myriad applications could be developed using stimuli-responsive drug delivery systems, which can
control the chronopharmacology of the therapeutic of interest in line with the chronobiology of the
condition to be treated. A variety of different therapeutics have been delivered using electroresponsive
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conductive scaffolds, as previously reviewed [46,47]. Most of these systems relied on the use of
conductive polymers (e.g., PPy, PANI and PEDOT) as the electroconductive/active moiety [46,47].
For instance, electrically controlled drug delivery from GO-nanocomposite PPy and silk-PPy films have
been previously reported [18,20]. However, the use of conjugated polymers tends to be limited due to
their poor processability in aqueous solution, brittleness and tendency to crack [48]. GO is readily
dispersible thanks to oxygen-containing functional groups on its surface, and it stands out for its ease
of processability. Graphene-based scaffolds were previously reported as drug delivery systems based
on the use of synthetic hydrogels and silk as the host materials [19,49], however, these systems relied
on the use of LMW drugs for short-term release. In this work, the prepared film samples were loaded
(doped) actively/electrostatically with a high-molecular-weight macromolecule - nerve growth factor-β
(NGF-β), and its release profile was determined by means of an enzyme-linked immunosorbent assay
(ELISA) which provides increased sensitivity and low limits of detection. The growth factor was
released either passively by diffusion (Figure 2, zoomed-in version shown in Figure S2) or actively
triggered upon the application of an electrical stimulus (Figure 3, stimulation paradigm depicted in
Figure S3). Passive release from the composite films was observed (ca. 1–2% at each time-point tested),
with a cumulative release of <10% over the course of the 10-day experiment. The application of a
reducing potential to the NGF-β-doped films triggered the release of the growth factor.
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i r 2. Delivery of nerv growth factor-β (NGF-β) from electroconductive/active silk-based scaffolds.
Cumulative release percentage from the films (n = 3 per type) with passive release. The differences
betwee the experimental groups were analyzed by two-way ANOVA using Tukey’s post hoc test for
multiple co parison (p-value with respect to pristine silk). n.s, nonsignifica t; ** p < 0.01.
Notable differences were observed between the electrically stimulated samples and the
non-stimulated ones. In particular, the amount of NGF-β released from the electrically stimulated films
was significantly higher (five- to eight-fold increase) than for the non-stimulated films (i.e., passive
release) at each time point tested, with an enhancement of up to 8–10% release at each time-point.
By day 10, most of the loaded therapeutic had been released from the samples via electrical stimulation.
The release of drugs over prolonged time periods is necessary for tissue repair and regeneration [21,50];
it obviates the need for repeated high dosing and improves the therapeutic index [17]. In addition to
providing long-term release, the system described in this work could be further modulated in terms of
the frequency pulse and duration used for stimulation. Notable differences were also observed for
the pristine silk sample, for which electrical stimulation resulted in ca. <20% cumulative drug release
over the course of 10 days, in comparison to the almost complete release of the growth factor from the
composite films. This clearly demonstrated the benefit of the presence of a conductive carbon-based
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dispersed phase in the hybrid composites, which enhances the electrically triggered release of this
therapeutic. However, no major differences in the drug release profiles were observed for the different
rGO loadings, likely because the conductivities of the samples in the hydrated state were similar.
The active delivery of NGF-β controlled in an on/off fashion is particularly interesting regarding
the potential control of its chronopharmacology for nerve repair. A variety of other therapeutics or
biological molecules (e.g., proteins, genes, siRNA molecules) could be delivered in a similar fashion
when exposed to electrical fields, where the loading and release profiles of the bioactives could be
correlated with their molecular descriptors (Tables S1 and S2).
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interactions, particularly the hazards that such materials present to the environment and life [51,52]. 
In vitro and in vivo tests showed that the choice of the specific graphene-based material incorporated 
in the composites and the method of use are of key importance regarding the risks associated with 
the application of such materials for biomedical applications [51,52]. Our in silico toxicity screening 
studies of these nanomaterials (Table S2) using Derek Nexus (Derek Nexus: 6.0.1, Nexus: 2.2.2) [53] 
confirmed some potential for graphene, GO and rGO to induce skin sensitization due to the presence 
of conjugated dienes in their structures, supported by observations in both in vitro and in vivo models 
[54–58]. Moreover, hydroxynaphthalene derivatives such as rGO were demonstrated as estrogen 
receptor modulators [59]. Our in silico mutagenicity screening studies of these nanomaterials (Table 
S2) using Sarah Nexus (Sarah Nexus: 3.0.0, Sarah Model: 2.0) also suggested that graphene, GO and 
rGO may be mutagenic, supported by in vitro and in vivo studies using graphene quantum dots [60], 
GO [61] and rGO [62]. Therefore, the specific method to use drug delivery devices based on these 
composites needs to be considered. In the case of the materials described in this work, it is possible 
to contemplate their use as microneedle patches or coatings on medical devices that would be 
removed after use and/or disposed of. 
4. Conclusions 
We report the development of electroresponsive biohybrid composites based on silk fibroin and 
reduced graphene oxide allowing the controlled release of a high-molecular-weight therapeutic over 





















































































































































































Figure 3. Electrically enhanced delivery of NGF-β from electroconductive/active silk-based scaffolds.
Cumulative release percentage from the films (n= 3 per type) with electrical stimulation. The differences
between the experimental groups were analyzed by two-way ANOVA using Tukey’s post hoc test for
multiple comparison (p-value with respect to pristine silk). **** p < 0.0001.
An important factor in the design of advanced composite biomaterials are material–tissue
interactions, particularly the hazards that such materials pre ent to the nvironment and life [51,52].
In vi r and in vivo tests showed that the choice of the s ecific graphene-based material incorporated
in the composites and t e method of use ar key importance r garding the risks associated with
t e applicat on of suc materials for biom dical applicatio s [51,52]. Our in silico toxicity screening
studies of these nano (Table S2) using Derek Nexus (Derek Nexu : 6.0.1, Nexu : 2.2.2) [53]
confirmed some p ten ial for graphene, GO and GO to induce skin s nsitization due to the presence
o conjugated dienes in their structures, supported by observations in b th in vitro and in vivo
models [54–58]. Moreover, hyd oxynaphthalene derivatives such as rGO were demonstrated as
estrogen receptor mo ulators [59]. Our in silico mutagenicity screening studies of these nanomaterials
(Table S2) using Sarah Nexus (Sarah Nexus: 3.0.0, Sarah Model: 2.0) also suggested that graphene,
GO and rGO may be mutagenic, supported by in vitro and in vivo studi s usin graphene quantum
dots [60], GO [61] and rGO [62]. Therefo e, the specific method to use drug delivery devices based
on these composites needs t be con idered. In t e case of the mat r als descr b d in this work, it is
possibl to contemplate their use as microne dle patches or coatings on medical devices that would be
removed af r use and/or disposed of.
4. Conclusions
We report the development of electroresponsive biohybrid composites based on silk fibroin and
reduced graphene oxide allowing the c ntrolled r lease of a high-m lecular-weight therapeutic over
prolon ed p riods of time. NGF-β was loaded electr statically and its elease was f cilitated over
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10 days by electrical stimulation in an on/off mechanism, with a five- to eight-fold increase compared
to the use of unmodified silk or the passive diffusion route. The conductivity of the system can be
tuned as the ratio of its components changes, and the release profile can be controlled by triggering.
These electroresponsive biohybrid composites based on silk could be manufactured in various other
forms (e.g., sponges, aligned fibres or guidance conduits) to potentially regenerate nerve tissue.
The concept of introducing electroconductive/active moieties into the network to impart conductive
properties to protein-based systems could be readily applied to other polypeptides found in nature or
recombinantly synthesized. The applications of the described system are numerous, from conductive
scaffolds that can be implanted directly into electrically excited tissues other than nerve to in vitro
platforms to grow electrically sensitive cells ex vivo. These findings represent a step forward in the
generation of biohybrids easily tailorable to multiple biological applications, where different levels of
conductivity may be desired.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/8/742/s1,
Figure S1: FTIR-ATR spectrum of the electroconductive/active silk-based films. Figure S2: Zoomed-in cumulative
NGF-β release (passive release) from the films. Figure S3: Electrical stimulation paradigm. Table S1: Molecular
descriptors. Table S2: Molecular-input line-entry system notations of the nanomaterials and molecules studied.
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